2023 is likely to be a year of normalisation for sales of analgesics in Belgium after three atypical years. 2020 saw a strong COVID-19 driven rush to pharmacists that was cut back by a stockpiling effect and a sharp fall in the incidence of influenza and colds due to measures imposed to limit the spread of the SARS-CoV-2 virus, which ultimately led to a sluggish performance.
The context of uncertain consumer incomes and higher price-sensitivity following the event of the pandemic and primarily the high rate of inflation in 2022 - and probably in 2023 - could accelerate the consumer switch to cheaper generic products to the detriment of mainstream brands. Prior to COVID-19, generics were already being increasingly preferred for self-medication purposes, providing growing competition for well-known brands such as Nurofen (Boots Healthcare), despite the latter having a high budget for television advertising and enjoying a global reputation.
Overall sales of analgesics could bear the brunt of a number of threats. Firstly, it may face indirect competition from preventive treatments in dietary supplements.
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
This report comes in PDF with additional info in Excel included.
Understand the latest market trends and future growth opportunities for the Analgesics industry in Belgium with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Analgesics industry in Belgium, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
Analgesics cover systemic and topical pain relievers. Products which include a pain-relief ingredient in addition to another core function are excluded (e.g. a sore throat remedy which includes paracetamol is excluded from the analgesics and instead is included in pharyngeal remedies).See All of Our Definitions
This report originates from Passport, our Analgesics research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!